UroGen Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . UroGen Pharma
URGN Stock  USD 11.53  0.08  0.70%   
UroGen Pharma financial statements provide useful quarterly and yearly information to potential UroGen Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on UroGen Pharma financial statements helps investors assess UroGen Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting UroGen Pharma's valuation are summarized below:
Gross Profit
81.5 M
Profit Margin
(1.40)
Market Capitalization
527.8 M
Enterprise Value Revenue
4.5851
Revenue
90.4 M
We have found one hundred twenty available fundamental trend indicators for UroGen Pharma, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check UroGen Pharma's current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to drop to about 237.4 M. In addition to that, Enterprise Value is likely to drop to about 209.5 M

UroGen Pharma Total Revenue

94.92 Million

Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.3 K, Interest Expense of 13.1 M or Selling General Administrative of 127.2 M, as well as many indicators such as Price To Sales Ratio of 4.8, Dividend Yield of 0.0 or Days Sales Outstanding of 97.34. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
  
Check out the analysis of UroGen Pharma Correlation against competitors.
To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

UroGen Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets300 M285.7 M99 M
Slightly volatile
Other Current Liabilities36.8 M35 M10.8 M
Slightly volatile
Total Current Liabilities48.2 M45.9 M15.1 M
Slightly volatile
Property Plant And Equipment Net2.3 M3.8 M1.7 M
Slightly volatile
Accounts Payable11.5 M10.9 M4.2 M
Slightly volatile
Cash180.6 M172 M55.9 M
Slightly volatile
Non Current Assets Total8.7 M9.6 M6.5 M
Slightly volatile
Cash And Short Term Investments248.5 M236.7 M80.8 M
Slightly volatile
Common Stock Shares Outstanding45 M42.9 M16.5 M
Slightly volatile
Liabilities And Stockholders Equity300 M285.7 M99 M
Slightly volatile
Other Current Assets10.4 M9.9 M3.9 M
Slightly volatile
Other Stockholder Equity837.1 M797.2 M284.2 M
Slightly volatile
Total Liabilities309.2 M294.5 M79 M
Slightly volatile
Total Current Assets289.9 M276.1 M92.3 M
Slightly volatile
Common Stock120.8 K115 K41.8 K
Slightly volatile
Property Plant Equipment1.7 M1.5 M1.2 M
Slightly volatile
Long Term Debt70.9 M121.7 M55.3 M
Slightly volatile
Common Stock Total Equity45.9 K72.5 K34.1 K
Slightly volatile
Short Term Investments46.3 M64.7 M32.7 M
Slightly volatile
Long Term Debt Total2.5 M4.2 M2.5 M
Slightly volatile
Capital Surpluse307.7 M561 M237.6 M
Slightly volatile
Property Plant And Equipment Gross8.5 M8.1 M2.4 M
Slightly volatile
Preferred Stock Total Equity10.4 K11.7 K12.8 K
Slightly volatile
Non Currrent Assets Other6.1 M5.8 M1.3 M
Slightly volatile
Other Assets367.9 K713 K355.4 K
Slightly volatile
Net Receivables10.6 M20.3 M5.8 M
Slightly volatile
Inventory9.7 M9.2 M2.5 M
Slightly volatile
Current Deferred Revenue5.3 M5 M1.4 M
Slightly volatile
Net Invested Capital59.8 M112.9 M71.1 M
Very volatile
Net Working Capital129.9 M230.2 M96.7 M
Slightly volatile
Capital Stock76.8 K115 K57.4 K
Slightly volatile
Short and Long Term Debt Total129.6 M123.4 M30 M
Slightly volatile
Capital Lease Obligations1.1 M1.7 M2.1 M
Slightly volatile
Non Current Liabilities Other5 M5.3 M8.6 M
Pretty Stable
Other Liabilities106.9 M101.8 M31.5 M
Slightly volatile
Short Term Debt1.4 M737.1 K1.7 M
Slightly volatile

UroGen Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization994.3 K1.2 M743.5 K
Slightly volatile
Selling General Administrative127.2 M121.2 M42.1 M
Slightly volatile
Other Operating Expenses196.5 M187.2 M76.1 M
Slightly volatile
Research Development35.1 M57.1 M26.5 M
Slightly volatile
Total Operating Expenses89.5 M178.3 M67.2 M
Slightly volatile
Interest Income9.3 M8.9 M2.2 M
Slightly volatile
Reconciled Depreciation1.4 M1.2 M837 K
Slightly volatile
Selling And Marketing Expenses38.1 M42.8 M46.7 M
Slightly volatile
Non Operating Income Net Other672.1 K1.2 M399.9 K
Slightly volatile

UroGen Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation14.1 M13.1 M10.6 M
Slightly volatile
Begin Period Cash Flow100.6 M95.8 M37.3 M
Slightly volatile
Depreciation994.3 K1.2 M743.5 K
Slightly volatile
Capital Expenditures453.1 K295 K347.9 K
Slightly volatile
End Period Cash Flow181.7 M173.1 M53.2 M
Slightly volatile
Change To Netincome15.3 M13.2 M11.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.85.05142.4 K
Very volatile
Days Sales Outstanding97.3481.973480.7887
Slightly volatile
Stock Based Compensation To Revenue0.140.145106
Very volatile
Capex To Depreciation0.240.24871.5032
Slightly volatile
EV To Sales4.294.51382.3 K
Very volatile
Inventory Turnover0.930.96250.7304
Slightly volatile
Days Of Inventory On Hand537379849
Slightly volatile
Payables Turnover0.50.81250.4179
Slightly volatile
Sales General And Administrative To Revenue3.2 K3 K1.4 K
Slightly volatile
Research And Ddevelopement To Revenue0.60.6321174
Very volatile
Capex To Revenue0.00310.00331.1871
Very volatile
Cash Per Share3.975.52014.2349
Slightly volatile
Days Payables Outstanding4274494 K
Slightly volatile
Current Ratio7.346.00966.6801
Pretty Stable
Receivables Turnover4.234.452794.271
Slightly volatile
Capex Per Share0.00650.00690.0317
Slightly volatile
Revenue Per Share1.142.10831.4245
Pretty Stable
Interest Debt Per Share1.723.16970.9926
Slightly volatile
Debt To Assets0.230.43190.131
Slightly volatile
Operating Cycle621461916
Slightly volatile
Days Of Payables Outstanding4274494 K
Slightly volatile
Long Term Debt To Capitalization1.021.07689.3254
Slightly volatile
Total Debt To Capitalization1.811.07680.9688
Slightly volatile
Quick Ratio7.255.80886.6151
Pretty Stable
Net Income Per E B T0.811.02280.9984
Slightly volatile
Cash Ratio5.23.7435.0472
Slightly volatile
Days Of Inventory Outstanding537379849
Slightly volatile
Days Of Sales Outstanding97.3481.973480.7887
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.0030.9905
Slightly volatile
Fixed Asset Turnover25.0523.85818.5077
Pretty Stable
Debt Ratio0.230.43190.131
Slightly volatile
Price Sales Ratio4.85.05142.4 K
Very volatile
Asset Turnover0.230.31640.4639
Slightly volatile

UroGen Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap237.4 M411 M250.1 M
Slightly volatile
Enterprise Value209.5 M367.2 M221.1 M
Slightly volatile

UroGen Fundamental Market Drivers

Cash And Short Term Investments236.7 M

UroGen Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About UroGen Pharma Financial Statements

UroGen Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5 M5.3 M
Total Revenue90.4 M94.9 M
Cost Of Revenue8.9 M9.3 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue3 K3.2 K
Research And Ddevelopement To Revenue 0.63  0.60 
Revenue Per Share 2.11  1.14 
Ebit Per Revenue(1.07)(1.12)
When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:
How To Invest In UroGen
Details
Is UroGen Stock a good investment?
Details
What is UroGen Pharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of UroGen Pharma Correlation against competitors.
To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.96)
Revenue Per Share
2.108
Quarterly Revenue Growth
0.044
Return On Assets
(0.26)
Return On Equity
(14.81)
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY